Tampa General Hospital's New Outpatient Cellular-Immunotherapy Unit
Tampa General Hospital (TGH) is elevating cancer treatment by opening an outpatient Cellular-Immunotherapy Transplant Unit at the TGH Cancer Institute. This groundbreaking program empowers patients battling aggressive blood cancers such as leukemias, lymphomas, and multiple myeloma to receive vital cell therapy treatments while returning home daily.
Empowering Patients with Innovative Outpatient Care
The new unit offers a transformative approach for adult patients undergoing advanced therapies like Chimeric Antigen Receptor (CAR) T-cell therapy and Bone Marrow Transplant (BMT). These patients can enjoy the comfort of home while receiving supportive care from a 24/7 caregiver who monitors their health and communicates with TGH clinicians. An essential part of qualifying for this program is for both the patient and caregiver to complete a mandatory educational course and meet specific medical criteria.
Significance of Outpatient Treatment
Dr. Eduardo Sotomayor, vice president and executive director of the TGH Cancer Institute, emphasizes the importance of this unit, stating that it marks a significant step forward in providing innovative treatments for complex cancers. “Patients can now receive essential cell therapy treatments as outpatients, making the process more comfortable and aligned with their lifestyles,” he explained.
CAR T-cell therapy harnesses the power of the patient’s own immune cells to attack cancer, making it a promising option for many. Meanwhile, BMT has long been a critical treatment for those at high risk of cancer relapse after conventional therapies.
Expert Leadership in Cancer Care
Leading the charge in this innovative unit is Dr. Ivan Borrello, a distinguished expert in multiple myeloma and the director of the Multiple Myeloma, Bone Marrow Transplant, and Cell Therapies Program at TGH. Dr. Borrello’s reputation stems from his groundbreaking work in developing unique cell therapy programs and his previous experience at the renowned Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
Benefits of an Outpatient Approach
The transition to outpatient treatments carries numerous advantages for patients. Dr. Borrello notes that many patients prefer the familiarity and comfort of their home environment. They tend to be more active and maintain better overall nutrition, contributing to improved psychological well-being. Studies indicate that patients receiving outpatient care often experience reduced depression and anxiety levels. Furthermore, some research suggests that outpatient care may lead to better overall treatment outcomes.
A 2021 systematic review reinforces these benefits, demonstrating that outpatient treatment models frequently yield higher safety and effectiveness ratings compared to inpatient care.
Comprehensive Patient Monitoring
Patients enrolled in the CTU benefit from a thorough assessment to determine if outpatient therapy is their best course of action. Throughout their treatment, the team closely monitors patient progress, while caregivers play a critical role in both patient management and recovery.
Daily outpatient visits allow patients to receive the same level of care and monitoring they would expect in a hospital setting, significantly shortening their hospital stay from three weeks to much more manageable daily clinic visits. This setup not only prioritizes their comfort but also ensures quick admission back to the hospital in case of any complications.
State-of-the-Art Facilities at TGH
The CTU provides a patient-centered environment featuring comfortable treatment options, including beds and recliners to enhance comfort during treatment. Jennifer Feeley, nurse manager for TGH's inpatient cell therapy unit, assures that the team's expertise matches that of the inpatient staff, ensuring that patients receive high-quality care regardless of their treatment setting.
In recent years, the TGH Cancer Institute has seen significant advancements in treatment options, notably with the 2022 launch of a cutting-edge Bone Marrow Transplant and Cell Therapies Unit. This progression underscores TGH's unwavering commitment to providing patients with comprehensive, innovative cancer care.
A Recognition of Quality Patient Care
Florida's only cancer center integrated with academic medicine, TGH Cancer Institute, is recognized among the top 50 cancer centers in the nation. Through extensive therapies, advanced diagnostic tools, and a coordinated approach, TGH stands out in the realm of patient care, demonstrating its dedication to nurturing health and wellness across the community.
With numerous accolades, including recognition by Newsweek as one of America's Best Cancer Hospitals, TGH remains focused on delivering exceptional services to its patients, showcasing its reputation as a leader in cancer treatment.
Frequently Asked Questions
What is the purpose of the new Cellular-Immunotherapy Transplant Unit?
The unit is designed to offer outpatient treatment options for patients with aggressive blood cancers, allowing them to receive vital therapies while staying at home.
What types of cancer does the unit treat?
The unit primarily focuses on aggressive blood cancers, including leukemias, lymphomas, and multiple myeloma.
How does outpatient treatment benefit patients?
Outpatient treatment allows patients to stay in the comfort of their own home, leading to better mental health, nutrition, and overall treatment outcomes.
Who leads the Cellular-Immunotherapy Transplant Unit?
Dr. Ivan Borrello, a leading expert in multiple myeloma, directs the unit, bringing extensive experience and expertise to the program.
How does TGH ensure quality care in the outpatient setting?
The team closely monitors patients and provides access to the same treatment level as inpatient care, ensuring prompt hospital admission if their condition changes.
